Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1974 Jun;53(6):1673–1678. doi: 10.1172/JCI107718

Role of Sweat in Accumulation of Orally Administered Griseofulvin in Skin

Vinod P Shah 1,2, William L Epstein 1,2, Sidney Riegelman 1,2
PMCID: PMC302663  PMID: 4830229

Abstract

Griseofulvin, an orally effective antimicrobial agent, appears in the stratum corneum within 4-8 h after oral administration. Griseofulvin distribution was found to be highest in the outermost layers of the stratum corneum (level I, 20.8±1.5 ng/mg) and lowest inside (level II, 10.0±1.5; level III, 7.5±2.2 ng/mg). In order to study the precise mechanism of griseofulvin transfer to stratum corneum, the role of sweat in the accumulation of griseofulvin was considered. Heat-induced total body sweating decreased the mean stratum corneum concentration of griseofulvin by 55%, and 200-300 ng of griseofulvin accumulated per ml of sweat. A silicone hydrophobic resin was used to differentiate between “wash-off” and carrier properties of sweat for griseofulvin. Prevention of transepidermal water and sweat loss by (a) topical application of formaldehyde-releasing cream to one palm, (b) occlusion by a 2 × 2-cm patch on one arm, and (c) wearing a rubber glove for 24 h, showed a lower griseofulvin concentration when compared to control areas in the same subjects. The results of the gloved hand experiment show that a complete equilibrium is established at all three levels of stratum corneum, thereby removing the reversed gradient. These results support the hypothesis that a “wick effect” is responsible for the observed reversed drug gradient within the stratum corneum. The results of the experiments suggest that sweat and transepidermal fluid loss play an important role in griseofulvin transfer in stratum corneum.

Full text

PDF
1673

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brusilow S. W., Gordes E. H. The permeability of the sweat gland to nonelectrolytes. Am J Dis Child. 1966 Oct;112(4):328–333. doi: 10.1001/archpedi.1966.02090130102009. [DOI] [PubMed] [Google Scholar]
  2. Epstein W. L., Shah V. P., Riegelman S. Griseofulvin levels in stratum corneum. Study after oral administration in man. Arch Dermatol. 1972 Sep;106(3):344–348. [PubMed] [Google Scholar]
  3. Harris D. R., Polk B. F., Willis I. Evaluating sweat gland activity with imprint techniques. J Invest Dermatol. 1972 Feb;58(2):78–84. doi: 10.1111/1523-1747.ep12551676. [DOI] [PubMed] [Google Scholar]
  4. Johnson H. L., Maibach H. I. Drug excretion in human eccrine sweat. J Invest Dermatol. 1971 Mar;56(3):182–188. doi: 10.1111/1523-1747.ep12260784. [DOI] [PubMed] [Google Scholar]
  5. ROTH F. J., Jr, BLANK H. The bioassay of griseofulvin in human stratum corneum. Arch Dermatol. 1960 May;81:662–666. doi: 10.1001/archderm.1960.03730050018004. [DOI] [PubMed] [Google Scholar]
  6. Randall W. C. QUANTITATION AND REGIONAL DISTRIBUTION OF SWEAT GLANDS IN MAN. J Clin Invest. 1946 Sep;25(5):761–767. doi: 10.1172/JCI101760. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Shah V. P., Riegelman S., Epstein W. L. Determination of griseofulvin in skin, plasma, and sweat. J Pharm Sci. 1972 Apr;61(4):634–636. doi: 10.1002/jps.2600610434. [DOI] [PubMed] [Google Scholar]
  8. THAYSEN J. H., SCHWARTZ I. L. The permeability of human sweat glands to a series of sulfonamide compounds. J Exp Med. 1953 Sep;98(3):261–268. doi: 10.1084/jem.98.3.261. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Vree T. B., Muskens A. T., van Rossum J. M. Excretion of amphetamines in human sweat. Arch Int Pharmacodyn Ther. 1972 Oct;199(2):311–317. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES